文献速递核素与放射性配体治疗肿瘤 PET/CT

99mTc-MIP-1404 SPECT/CT作为177Lu-PSMA治疗转移性去势抵抗性前列腺癌的伴随诊断

99mTc-MIP-1404 SPECT/CT Companion Diagnostic for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2025-03-03

回顾性分析46例转移性去势抵抗性前列腺癌患者,评估99mTc-MIP-1404 SPECT/CT用于基线分期和177Lu-PSMA放射性配体治疗资格评估的可行性、诊断性能和预测价值。99mTc-MIP-1404显像与治疗后177Lu-PSMA扫描在210个定位中206个一致(κ=0.957),摄取高于肝脏可识别应答者并关联更长无进展生存期。结论认为99mTc-MIP-1404显像适合评估晚期转移性去势抵抗性前列腺癌患者的放射性配体治疗资格。

要点

  • 99mTc-MIP-1404扫描图像质量在98%的病例中评为优秀。
  • 与177Lu-PSMA扫描在210个定位中206个一致,κ=0.957(95%CI 0.916-0.999)。
  • 摄取高于肝脏者应答率更高(P=0.0115),中位无进展生存期146天 vs 96天。

核心结论

  • 99mTc-MIP-1404显像适合评估晚期转移性去势抵抗性前列腺癌患者的放射性配体治疗资格。
  • 治疗前摄取强度可预测177Lu-PSMA放射性配体治疗的应答。

研究设计与样本

  • 回顾性分析46例接受99mTc-MIP-1404平面显像和SPECT/CT用于分期及177Lu-PSMA放射性配体治疗资格评估的患者数据。
  • 将99mTc-MIP-1404结果与随后开始放射性配体治疗的35例患者的治疗后177Lu-PSMA扫描结果进行比较。
  • 评估99mTc-MIP-1404扫描摄取强度的预测和预后意义。

主要发现

  • 99mTc-MIP-1404扫描图像质量在98%的病例中评为优秀。
  • 影像结果在210个定位中206个一致,与177Lu-PSMA扫描几乎完全一致(κ=0.957 [95%CI 0.916-0.999])。
  • 摄取高于肝脏识别应答者(P=0.0115),并关联延长无进展生存期(中位146天 vs 96天;进展风险比0.3838 [95%CI 0.1721-0.8556];P=0.0192)。
  • 多变量分析中,99mTc-MIP-1404摄取高于肝脏是治疗应答的独立预测因素(比值比12.37 [95%CI 1.613-203.3];P=0.0319)。
  • 然而,27%的应答者摄取不高于肝脏。

关键数值与推荐

  • 视觉评分采用3分制评估转移性摄取。
  • 与177Lu-PSMA扫描一致性κ=0.957(95%CI 0.916-0.999)。
  • 摄取高于肝脏预测应答的P=0.0115,独立预测因素比值比12.37(95%CI 1.613-203.3;P=0.0319)。
  • 摄取高于肝脏者中位无进展生存期146天 vs 96天,进展风险比0.3838(95%CI 0.1721-0.8556;P=0.0192)。

临床怎么用

  • 99mTc-MIP-1404显像可用于评估晚期转移性去势抵抗性前列腺癌患者的放射性配体治疗资格。
  • 治疗前99mTc-MIP-1404摄取强度可预测177Lu-PSMA放射性配体治疗的应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to determine the feasibility, diagnostic performance, and predictive value of 99mTc-MIP-1404 SPECT in patients undergoing baseline staging and assessment of eligibility for prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) for metastatic castration-resistant prostate cancer. Methods: Data of 46 patients undergoing 99mTc-MIP-1404 planar scintigraphy and SPECT/CT for staging and assessment of eligibility for 177Lu-PSMA RPT were retrospectively analyzed. Overall image quality was assessed, and images were visually analyzed for the presence and localization of pathologic uptake. Metastatic uptake was visually scored using a 3-point scale. 99mTc-MIP-1404 findings were compared with the results of posttherapeutic 177Lu-PSMA scans in patients subsequently commencing RPT (n = 35). The predictive and prognostic significance of uptake intensity in 99mTc-MIP-1404 scans was evaluated. Results: The image quality of 99mTc-MIP-1404 scans was rated as excellent in 98% of cases. Imaging results were concordant in 206 of 210 localizations, demonstrating almost perfect agreement with 177Lu-PSMA scans (κ = 0.957 [95% CI, 0.916-0.999]). Uptake intensity higher than liver uptake identified responders (P = 0.0115) and was associated with prolonged progression-free survival (median, 146 vs. 96 d; hazard ratio for progression, 0.3838 [95% CI, 0.1721-0.8556]; P = 0.0192). In multivariable analysis, 99mTc-MIP-1404 uptake higher than in liver emerged as an independent predictor of treatment response (odds ratio, 12.37 [95% CI, 1.613-203.3]; P = 0.0319). Nevertheless, 27% of responders demonstrated uptake no higher than that in the liver. Conclusion: 99mTc-MIP-1404 imaging is suitable for assessment of eligibility for RPT in patients with advanced metastatic castration-resistant prostate cancer. In particular, pretherapeutic uptake intensity is predictive of response to 177Lu-PSMA RPT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Derlin T, Widjaja L, Harke NN, et al. 99mTc-MIP-1404 SPECT/CT Companion Diagnostic for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025. PMID: 39915124. doi:10.2967/jnumed.124.269319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。